CClinicalTrials.gg
CompletedNCT05890989Updated Jun 6, 2023

Relationship of Epicardial Adiposity With Sedentary Time, Physical Activity and Performance in Hypertensives

An observational study in Hypertension, sponsored by Karamanoğlu Mehmetbey University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Karamanoğlu Mehmetbey University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Epicardial adipose tissue is associated with the development of cardiovascular disease and its increase is positively correlated with blood pressure elevation in hypertensive individuals. In the literature, being physically active has been shown to be effective in the treatment of hypertension and reduction of epicardial adipose tissue thickness. The aim of this study was to evaluate the relationship between epicardial adipose tissue thickness and sedentary time, physical activity level and physical performance in patients with hypertension. The study included 40 patients with hypertension. The physical and demographic characteristics of the participants were collected using a sociodemographic form. Waist/hip circumference was measured with tape measure and epicardial adipose tissue thickness with echocardiography device. Physical activity levels and sedentary time were recorded via IPAQ-7. Physical performance was determined using the 30-s sit-and-stand test. There is no previous study in the literature evaluating the relationship between epicardial adipose tissue thickness and sedentary time and physical activity levels in hypertensive patients. With this study, we aim to contribute to the literature by filling this deficiency.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Epicardial adipose tissue
  • Hypertension
  • Physical activity
  • Sedentary time
  • Physical performance
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 964 are open to participants now.

This study's enrollment of 40 is below the median of 210 across 1,358 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Karamanoğlu Mehmetbey University is the lead sponsor of 65 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Volunteers who had been diagnosed with hypertension for at least 6 months

Inclusion criteria

  • Volunteering to participate in the study
  • Being diagnosed with hypertension for at least 6 months
  • Speaking Turkish
  • to be able to read and write,
  • To be between 18-65 years old

Exclusion criteria

Exclusion Criteria:

  • Severe valvular disease
  • be heart failure
  • being cardiomyopathy
  • having chronic kidney disease
  • being thyroid diseases
  • active infectious or inflammatory diseases
  • serious psychiatric illnesses such as panic disorder or major depression
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • INCREASED EPICARDIAL ADIPOSIS TISSUE

    Diagnostic Test: EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT

Interventions

  • Diagnostic testEPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT

    EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.

06

What researchers measure

Primary outcomes

  1. EPICARDIAL ADIPOSIS TISSUE MEASUREMENT

    All patients underwent transthoracic echocardiography conducted by a single cardiologist using a Philips HD11XE (Philips Medical Systems) device in the left lateral decubitus position by the standard technique. Epicardial fat thickness was measured in the parasternal long axis imaging window, using the aortic annulus as an anatomical indicator for vertical measurement, and the widest part of the region from the right ventricular free wall to the pericardium at the end of the systole.

    Time frame: measured at admission

Secondary outcomes

  1. PHYSICAL PERFORMANCE

    The physical performance of the participants was evaluated with the 30-second sit-and-stand test. While seated in a chair with a seat height of 43.2 cm and a supported back, the patient was asked to stand up and sit down as quickly as possible while crossing his/her hands over his/her chest. The 30-second duration of the test was monitored with a stopwatch and the number of times the participant stood up and sat down was noted. Two trials were performed before the test.

    Time frame: measured at admission

Other outcomes

  1. PHYSICAL ACTIVITY

    Physical activity level was evaluated with the Turkish version of the International Physical Activity Questionnaire-7 (IPAQ-7), whose reliability and validity were confirmed by Saglam et al. The IPAQ-7 is a seven-item questionnaire that assesses severe physical activity (duration: min and frequency: day), moderate physical activity (duration: min and frequency: day), and walking time of at least 10 minutes (frequency: day) over the previous seven days. The metabolic equivalent of task (MET) corresponding to the basal metabolic rate is converted from severe and moderate activity and walking periods, and the overall physical activity score (MET- min/week) is determined

    Time frame: measured at admission

  2. SEDENTARY TIME

    Sedentary time was questioned with the International Physical Activity Questionnaire-7 (IPAQ-7), the reliability and validity of which was confirmed by Saglam et al.

    Time frame: measured at admission

07

Study locations

1 site
  • Karamanoğlu Mehmetbey University
    Karaman, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05890989
Lead sponsor
Karamanoğlu Mehmetbey University
Collaborators
Karaman Training and Research Hospital
Responsible party
Emine Tunç Süygün (LECTURER, Karamanoğlu Mehmetbey University) — Principal investigator
First posted
Jun 6, 2023
Start date
Dec 6, 2021
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022
Last update
Jun 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion